These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 24382431)
1. Staging, risk assessment and screening of breast cancer. Yalcin B Exp Oncol; 2013 Dec; 35(4):238-45. PubMed ID: 24382431 [TBL] [Abstract][Full Text] [Related]
2. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Piver MS Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging. Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of hereditary risk in a mammography population. Jones JL; Hughes KS; Kopans DB; Moore RH; Howard-McNatt M; Hughes SS; Lee NY; Roche CA; Siegel N; Gadd MA; Smith BL; Michaelson JS Clin Breast Cancer; 2005 Apr; 6(1):38-44. PubMed ID: 15899071 [TBL] [Abstract][Full Text] [Related]
5. Hereditary breast/ovarian cancer syndrome: a primer for obstetricians/gynecologists. Meaney-Delman D; Bellcross CA Obstet Gynecol Clin North Am; 2013 Sep; 40(3):475-512. PubMed ID: 24021253 [TBL] [Abstract][Full Text] [Related]
6. Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved Populations. Robinson LS; Hendrix A; Xie XJ; Yan J; Pirzadeh-Miller S; Pritzlaff M; Read P; Pass S; Euhus D; Ross TS EBioMedicine; 2015 Nov; 2(11):1827-33. PubMed ID: 26870808 [TBL] [Abstract][Full Text] [Related]
7. Screening of women at high risk for breast cancer. Narod SA Prev Med; 2011 Sep; 53(3):127-30. PubMed ID: 21745498 [TBL] [Abstract][Full Text] [Related]
8. Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria. Singer CF; Muhr D; Rappaport C; Tea MK; Gschwantler-Kaulich D; Fink-Retter A; Pfeiler G; Berger A; Sun P; Narod SA Clin Genet; 2014 Jan; 85(1):72-5. PubMed ID: 23772696 [TBL] [Abstract][Full Text] [Related]
9. Breast cancer screening, outside the population-screening program, of women from breast cancer families without proven BRCA1/BRCA2 mutations: a simulation study. Jacobi CE; Nagelkerke NJ; van Houwelingen JH; de Bock GH Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):429-36. PubMed ID: 16537697 [TBL] [Abstract][Full Text] [Related]
10. Use of breast MRI surveillance in women at high risk for breast cancer: a single-institutional experience. Elmore L; Margenthaler JA Ann Surg Oncol; 2010 Oct; 17 Suppl 3():263-7. PubMed ID: 20853044 [TBL] [Abstract][Full Text] [Related]
11. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145 [TBL] [Abstract][Full Text] [Related]
12. Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening. Hoskins KF; Zwaagstra A; Ranz M Cancer; 2006 Oct; 107(8):1769-76. PubMed ID: 16967460 [TBL] [Abstract][Full Text] [Related]
13. Five-year analysis of magnetic resonance imaging as a screening tool in women at hereditary risk of breast cancer. Kam JK; Naidu P; Rose AK; Mann GB J Med Imaging Radiat Oncol; 2013 Aug; 57(4):400-6. PubMed ID: 23870334 [TBL] [Abstract][Full Text] [Related]
14. Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies. Long KC; Kauff ND Curr Opin Oncol; 2011 Sep; 23(5):526-30. PubMed ID: 21734577 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Fostira F; Tsitlaidou M; Papadimitriou C; Pertesi M; Timotheadou E; Stavropoulou AV; Glentis S; Bournakis E; Bobos M; Pectasides D; Papakostas P; Pentheroudakis G; Gogas H; Skarlos P; Samantas E; Bafaloukos D; Kosmidis PA; Koutras A; Yannoukakos D; Konstantopoulou I; Fountzilas G Breast Cancer Res Treat; 2012 Jul; 134(1):353-62. PubMed ID: 22434525 [TBL] [Abstract][Full Text] [Related]
17. Screening for hereditary breast cancer. Dent R; Warner E Semin Oncol; 2007 Oct; 34(5):392-400. PubMed ID: 17920893 [TBL] [Abstract][Full Text] [Related]
18. Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2. Goldfrank D; Chuai S; Bernstein JL; Ramon Y Cajal T; Lee JB; Alonso MC; Diez O; Baiget M; Kauff ND; Offit K; Robson M Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2311-3. PubMed ID: 17119064 [TBL] [Abstract][Full Text] [Related]
19. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy. Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873 [TBL] [Abstract][Full Text] [Related]
20. MRI screening in a clinic population with a family history of breast cancer. Yu J; Park A; Morris E; Liberman L; Borgen PI; King TA Ann Surg Oncol; 2008 Feb; 15(2):452-61. PubMed ID: 18026801 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]